PD40-11 CLINICAL ACTIVITY OF NIVOLUMAB IN ADVANCED HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER (HLRCC)-ASSOCIATED KIDNEY CANCER

Authors :: Maria Merino
Jeanny B. Aragon-Ching
Ramaprasad Srinivasan
Sandeep Gurram
Paul Denis Leger
Munjid Al-Harthy
Alexis Rompré-Brodeur
Jaime R. Merchan
Beatriz Walter Rodriguez
Ashkan A. Malayeri
Daniel Girardi
Julia Friend
W. Marston Linehan
Rabindra Gautam
Arash Rezazadeh Kalebasty
Source :: Journal of Urology. 206
Publication Year :: 2021
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2021.
Abstract: INTRODUCTION AND OBJECTIVE:Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) is a hereditary condition characterized by an increased risk for a clinically aggressive papillary renal cell c...

Subjects :: business.industry
Urology
Cell
urologic and male genital diseases
medicine.disease
Leiomyomatosis
medicine.anatomical_structure
Increased risk
Cancer research
medicine
Hereditary leiomyomatosis and renal cell carcinoma
Cell cancer
Nivolumab
business
Kidney cancer

Full Text Access

Tools